Latest Teriparatide Stories

Greater Reduction in the Risk of Vertebral Fracture is One of the Greatest Unmet Needs in Osteoporosis and Osteopenia, According to a New Report from Decision Resources BURLINGTON, Mass., April 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is one of the attributes that...

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The...

INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months in postmenopausal women with osteoporosis, based on additional analysis of data from the SHOTZ trial. Results, which were presented in an oral presentation at the 2012 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Minneapolis, MN, clearly differentiate the...

BOONTON, N.J., Oct. 15, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women was the subject of an oral presentation given by Morten Karsdal, MSc, PhD, Chief Executive Officer of Nordic Bioscience, at...

THOUSAND OAKS, Calif., Sept. 20, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia(®) (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia, the first FDA-approved RANK Ligand inhibitor, is a subcutaneous injection administered by a health care professional every six months. "While osteoporosis and osteoporosis-related fractures are more...

INDIANAPOLIS, Aug. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced data from a Phase III trial comparing the effects of FORTEO(®) (teriparatide [rDNA origin] injection) and risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures. The study showed no difference between FORTEO and risedronate on the primary endpoint of at least a 30 percent reduction in worst back pain from baseline to six months of therapy, as assessed by a...

A new analysis of popular bone-building drugs by the US Food and Drug Administration (FDA) could prompt millions of women to rethink their use of such drugs, even though the agency fell short of issuing specific recommendations. The FDA said doctors need to reassess which women are likely to benefit from bisphosphonates such as Fosamax, Actonel and Reclast, given the lack of concrete evidence that taking them over long periods really helps them and the possibility that they can put some...

Seven Dutch women suffering from osteoporosis received bone-strengthening medication from implanted microchips as part of a first-of-its kind study of wirelessly controlled drug-releasing devices, according to research published Thursday in the journal Science Translational Medicine. According to Lauran Neergaard of the Associated Press (AP), the study, which was funded by Massachusetts-based implantable drug delivery device developer MicroCHIPS, Inc and headed up by MIT professors Robert...

BOONTON, N.J., Jan. 9, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today provided a business outlook for 2012 and highlighted multiple near-term catalysts that have the potential to monetize assets and unlock significant value over the next 12 months. Management believes the key elements are in place to address the Company's debt and begin restructuring the balance sheet in 2012. Unigene's CEO, Senior Management and Board of Directors signaled confidence...

Randomized controlled trial A simple physician notification system can help prevent further fractures in osteoporotic patients who have had already had fractures, according to a study in CMAJ (Canadian Medical Association Journal). Patients who have had a major fracture because of osteoporosis do not undergo testing for bone mineral density or receive medications to help prevent additional fractures. Recent 2010 Canadian clinical practice guidelines for osteoporosis care noted this...